Accel and Insight Partners led a $50m Series A round in PhaseV.

Investment firms Accel and Insight Partners led a $50m Series A round in PhaseV, a AI/ML-driven clinical development firm, with participation from Viola Ventures, EXOR and LionBird. The funding will allow PhaseV to grow its vertical AI platform to provide holistic solutions for clinical development. It follows the rapid market adoption of PhaseV’s AI/ML-based platform by over 30 global pharma companies for clinical development. The platform is currently used across more than 20 therapeutic areas, including neurology, oncology, GI disorders, immunology, metabolic diseases, rare diseases, and others.